Summary & Overview
HCPCS J0687: Cefazolin Sodium Injection, 500 mg
HCPCS Level II code J0687 identifies a 500 mg injection of cefazolin sodium, specified as not therapeutically equivalent to J0690. This code designates a commonly used parenteral first-generation cephalosporin for treatment or prophylaxis of susceptible bacterial infections in acute care and ambulatory settings. Nationally, accurate coding for antibiotic injectables matters for clinical documentation, formulary management, and reimbursement alignment across payers.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare and Medicare. The publication outlines payer coverage patterns, available reimbursement benchmarks, and operational considerations for billing and claims submission for injectable cefazolin preparations.
Readers will find a concise explanation of the clinical context for J0687, expected sites of service where the drug is administered, common coding and billing implications, and a summary of payer coverage themes. The report highlights policy updates that affect injectable drug coding and claims processing, typical billing modifiers used in practice (list provided separately), and where data was not available in the input. This resource serves providers, billers, and policy analysts seeking a national overview of coding and coverage for cefazolin injection represented by J0687.
Billing Code Overview
HCPCS Level II code J0687 represents an injection of cefazolin sodium, specified as 500 mg and noted as not therapeutically equivalent to J0690. The service is an antibiotic injectable medication intended for intravenous or intramuscular administration and is generally used for treatment or prophylaxis of susceptible bacterial infections.
Service Type: Drug administration — injectable antibiotic
Typical Site of Service: Hospital outpatient department, inpatient hospital, emergency department, ambulatory surgical center, or physician office depending on clinical context and administration needs.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult admitted to a medical or surgical unit with a suspected or confirmed bacterial infection requiring parenteral first‑generation cephalosporin therapy. For example, a 62‑year‑old man presents with signs of cellulitis of the lower extremity with erythema, warmth, and systemic symptoms; wound culture pending. The admitting team orders J0687 (cefazolin sodium, 500 mg) to be administered intravenously per hospital antimicrobial protocol while awaiting culture results. The clinical workflow includes: admission evaluation and order entry by the prescribing physician or advanced practice provider; verification and dose preparation by pharmacy, including allergy and renal dosing checks; IV access confirmation by nursing; administration and documentation of the dose (including route, time, lot number); monitoring for infusion reactions; and dose adjustments or discontinuation based on culture results and stewardship recommendations. Typical sites of service are the inpatient hospital unit, emergency department, observation unit, and outpatient infusion center when IV antibiotic therapy is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure performed by originating site (not commonly used for HCPCS drugs) | Rarely used; include only if payer-specific rules require an originating site indicator for facility reporting |